Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.52 |
| ▸ | RELA | Q04206 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13956743 | 0.79 | NPC1 (0.71) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL14096079 | 0.79 | MAPT (0.78) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL4367642 | 0.79 | RAB9A (0.48) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL13956746 | 0.77 | MAPT (0.74) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL13956799 | 0.76 | ALDH1A1 (0.54) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL13956804 | 0.76 | ALDH1A1 (0.46) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL4538070 | 0.76 | MAPT (0.73) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL2868313 | 0.76 | NPC1 (0.49) | MAPTALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL3423738 | 0.76 | SMN1; SMN2 (0.51) | MAPTALDH1A1NPC1KMT2ARAB9A | |
| SCHEMBL14096080 | 0.76 | MAPT (0.76) | MAPTALDH1A1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | claimed |
| US-20040138205-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | claimed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-7094807-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138205-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, TPMT | MAPT 3454/4885ALDH1A1 310/4885NPC1 107/4885 |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | MAPT 4038/4885ALDH1A1 2930/4885NPC1 886/4885 |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, SLC10A1 | MAPT 3752/4885ALDH1A1 221/4885NPC1 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.